If there is any silver lining from the economic and public health fall-out of Covid-19, it may be a renewed sense of perspective. As more of us spent far more time staying at home than usual with the governmental national “Stay at Home” orders, we had more time on our hands than usual to reflect on what’s most important to us.
We all remember the talk of Ibuprofen possibly being a danger when taken while having the Covid-19 virus. As experts recommended a fast shift in moving to Acetaminophen, in addition to taking large amounts of vitamins C, D and Zinc, they had the general public totally focused on the healthiest regimen to combat and defend oneself against the fast moving virus.
Now, consumers have increasingly demonstrated a wholesale shift in their values – with a greater emphasis on health, wellness, and peace of mind. Consumers are increasingly seeking out items at the grocery store that don’t only fit their budget, but more and more are also now focused on a healthier lifestyle.
The companies that thrive in the years ahead will be the ones prepared to tap into this trend. Med-X Inc., as an example, demonstrates a better path forward for consumers with all-natural alternatives to the pain management and pest control industries. Med-X’s flagship products and services division, Nature-Cide, is now going head-to-head with big chemical and big pharma which have dominated the markets for decades – with devastating consequences for good health and our ecology.
The days of poisonous chemicals and harmful pharmaceutical products must end, specifically in the areas of pest control and pain management. However, that will only happen with viable, superior, and cost-effective alternatives in the marketplaces.
Nature-Cide – Helping to Control the Global Mosquito Population and Beyond
As we continue to see a boom of consumers seeking environmentally friendly products particularly in the area of pest management. Med-X’s Nature-Cide division continues to prove that there are viable Eco-friendly, all-natural alternatives to professional pest control.
Vector-borne diseases kill more than 700,000 people around the globe each year, and 20-40% of global crop production is lost annually to pest infestations. As the New York Times recently highlighted, new invasive species and pests drain trillions from economies around the world in emerging markets like Africa. Yet, the industry continues to be dominated by using synthetic chemicals products. The management at Med-X saw a clear need that was not being addressed in the market – even as the global pest control industry which is projected to grow from $18 billion in 2018 to as much as $27 billion in 2025. That’s 6% annual growth in market size. Studies prove that exposure to pesticides remains closely linked to rising levels of cancer, chronic disease, and damage to our natural environment.
Just consider the continued devastation unleashed across large swaths of the world even today by Malaria, estimated to have killed 409,000 people in 2019, particularly young children in sub-Saharan Africa. Imagine the “win-win” scenarios possible by scaling more environmentally-friendly pesticides at a rapid pace. That’s why controlling the global mosquito population has emerged as one of the world’s top public health priorities, even amidst the ongoing Covid-19 pandemic.
The team at Med-X, Inc. clearly believes there’s a better way, as they track the clear demand for alternatives, offering approaches that are:
You don’t have to take their word for it. Just listen to the experts at the Journal of the Florida Mosquito Control Association. (If any place is well versed in the need for effective pesticides, it’s the state of Florida.)
The Journal reported a two-year study by scientist Dr. Ruide Xue from the Anastasia Mosquito Control District in Florida (which was conducted without Med-X management knowledge). The results were conclusive and seemingly unexpected by the scientists involved in the study. Nature-Cide was the single top-performing pesticide for mosquito control going head-to-head with the most popular synthetic chemicals currently being used in the pest control industry (See charts below). The study concluded that “It was surprising to find that Nature-Cide formulated as a multi-purpose insecticide, outperformed all other products in both laboratory (Fig. 3) and field (Fig. 4) trials’.
Average percent 24 h mortality with standard errors of the mean (ANOVA/Tukey HSD at 95% confidence, P < 0.001) of Aedes albopictus (Skuse) for each of five residual spray formulations, Nature-Cide All-Purpose Commercial Concentrate (clove oil, cottonseed oil; 25-100 mL/L), Cyzmic CS (lambda-cyhalothrin; 1.5-3.0 mL/L), DeltaGard (deltamethrin; 2-12 mL/L), Onslaught (fenvalerate; 4-8 mL/L), and Essentria IC3 (Rosemary oil, peppermint oil; 23-47 mL/L) applied at low, mid, and high label rates. Control bioassays produced 0% mortality.
Field collections of adult Ae. albopictus from 5 sites treated with residual insecticides paired with 5 untreated control sites, with rainfall data (cm) from a centrally located weather station to provide context for patterns of mosquito population change. Each graph includes results from collections for 3 weeks prior to application of the residual treatment that confirmed presence of Ae. albopictus at all treatment and control sites. We initiated experimental treatments at Week 4 with the low rate which, with the exception of Nature-Cide, did not substantially reduce Ae. albopictus abundance. We applied mid-rate treatments at Week 8 resulting in Ae. albopictus reduction at all treatment sites: Nature-Cide and Onslaught (~90% reduction), Delta-Gard (~79%), Essentria IC3 (64%), and Cyzmic CS (~36%). We were not able to conduct field trials at the high label rate because of time limitations.
A few key take-aways from the report:
“Millions of lives are lost due to vector-borne diseases with a growth rate annually of over 5%. Imagine the global impact within our reach if we can eradicate diseases like Malaria that claim so many lives each year. We believe we have the solution to end this world-wide crisis,” states Matthew Mills, COO ofMed-X, Inc.
Most recently, Orkin Pest Control named Los Angeles as the #1 hot spot for mosquito population in the Top 50 City Mosquito Report published on May 24, 2021. “More and more companies like Orkin franchisees are learning about Nature-Cide products advancements, and we are grateful that so many pest control companies are putting the Nature-Cide products and protocols to work in the field regularly,” states Mills.
It’s practically become fashionable today to be optimistic about the long-term global outlook for challenges like protecting the environment and battling global disease. “Results like the progress we have seen with Nature-Cide products should give us all cause for optimism – and remind us of how much we can still achieve with all of the science and technology at our fingertips today. Sometimes nature just needs a little science to unlock its potential,” states Mills.
ABOUT MED-X, INC.
Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid, and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand.
For more information regarding Med-X, Inc., please visit www.medx-rx.com, email email@example.com or call 818-349-2870.
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as “expected,” “anticipated,” “projected” and “forecasted.” Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.